TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 27, 2019

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Granulomatosis With PolyangiitisWegener Granulomatosis

Interventions

DRUG

Trimethoprim Sulfamethoxazole

Dosage: 160mg-800mg Frequency: 2 times a day Dosage Form: Pill (oral) Duration: 4 weeks

Trial Locations (1)

Perelman Center for Advanced Medicine, Philadelphia

All Listed Sponsors

lead

University of Pennsylvania

OTHER

NCT03919435 - TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis | Biotech Hunter | Biotech Hunter